Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Your donations help support people living with type 1 diabetes today and fund the best treatment and cure research, no matter where in the world it takes place.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This World Diabetes Day, we’re inviting you to celebrate by wearing your most joyful, whimsical and downright wonderful outfits.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > About BTT1D & Our Impact > Our research > Research projects > Finding new ways to treat hypoglycaemia unawareness
Up to 30 per cent of people with type 1 have some degree of hypoglycaemia unawareness, meaning that they don’t develop, or don’t recognise, the symptoms of a hypo. This can significantly increase their risk of a severe hypo.
Dr Weightman-Potter is studying the way the brain detects hypos, to find ways to treat hypoglycaemia unawareness, so that people with type 1 can live safer lives without the fear of a sudden, unexpected hypo.
The brain is an important sensor of changes in blood glucose, so Dr Weightman-Potter will look at the brain’s role in causing hypo unawareness.
In particular, his team previously showed that after repeated episodes of hypoglycaemia, a special type of brain cell becomes less dependent on glucose for energy, and prefers to use fats instead.
For his Breakthrough T1D UK-funded project, Dr Weightman-Potter will first test his theory that these cells’ switch to fat as a source of energy is impairing the way the brain senses and responds to low blood glucose levels.
If this is the case, he will see if the change is reversible by using drugs and genetic manipulation to make the brain cells less reliant on fat for energy, and testing their ability to detect hypoglycaemia.
Finally, Dr Weightman-Potter hopes to investigate the precise cellular mechanisms that are causing this switch to fat-burning, to determine what treatments could be used to target the process and reverse it in people with type 1.
People with hypoglycaemia unawareness are six to eight times more likely to have a severe hypo, where they need help to bring their levels back to a safe range.
Worryingly, the rate of hypoglycaemia unawareness has not changed in the last 20 to 30 years, despite the advent of more tailored insulins and continuous glucose monitoring technology.
Dr Weightman-Potter’s work could offer a new way to restore the brain’s awareness of hypoglycaemia, saving up to 30 per cent of people with type 1 diabetes from the fear of a sudden, severe hypo – and enabling them to more effectively manage their blood glucose levels.
In the UK, we’re funding Professors Stephanie Amiel and Pratik Choudhary to find out if a talking therapy programme can ‘re-wire’ the brain and restore hypo awareness in people with type 1.
We also support Professor Rory McCrimmon’s research into whether high-intensity exercise can improve hypo awareness and also improve the body’s response to hypos.
This award will help to fund the next generation of immunotherapy research, enabling more efficient clinical trials, in more locations, so that promising treatments can reach people sooner.
This project aims to overcome two major roadblocks to developing and licensing immunotherapies for people newly diagnosed with type 1 diabetes.
Dr Bewick is exploring ways to improve the health, performance and number of beta cells in the body, so that people with type 1 can be less reliant on insulin pumps and injections – or even, one day, live without them completely.
This project is looking at a new way to turn stem cells into beta cells in the lab, to better understand what conditions make this process happen efficiently.